Efficacy of TAK-457, a Novel Intravenous Triazole, against Invasive Pulmonary Aspergillosis in Neutropenic Mice

AUTOR(ES)

Hayashi, Ryogo

FONTE

American Society for Microbiology

RESUMO

TAK-457 is an injectable prodrug of TAK-456, which is a novel oral triazole compound with potent antifungal activity. The in vivo efficacy of TAK-457 was evaluated in two models of invasive pulmonary aspergillosis with CDF1 mice and CBA/J mice with transient neutropenia induced by cyclophosphamide. Against the infection in CDF1 mice, treatment with 10 mg of TAK-457 and 1 mg of amphotericin B/kg reduced the fungal burden in lungs and rescued all mice. In the infection model with CBA/J mice, TAK-457 at a dose of 10 mg/kg significantly prolonged the survival time of mice, showing significant reduction of lung chitin levels and the plasma β-d-glucan levels. On the other hand, amphotericin B at 1 mg/kg which was a maximum tolerable dose showed slight but not significant prolongation of survival time of mice, although it also reduced the lung chitin levels and the plasma β-d-glucan levels to a lower extent but still significantly. These results suggest that TAK-457 is a promising candidate for development for the treatment of invasive aspergillosis in humans.

Documentos Relacionados

• Efficacy of CS-758, a Novel Triazole, against Experimental Fluconazole-Resistant Oropharyngeal Candidiasis in Mice
• Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.
• Apparent pulmonary mycetoma following invasive aspergillosis in neutropenic patients.
• Long-Circulating Immunoliposomal Amphotericin B against Invasive Pulmonary Aspergillosis in Mice
• Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.